Trevena Dirección

Dirección controles de criterios 2/4

El CEO de Trevena's es Carrie Bourdow , nombrado en Oct 2018, tiene una permanencia de 5.5 años. compensación anual total es $1.00M, compuesta por 65.4% salario y 34.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.51% de las acciones de la empresa, por valor de $36.17K. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 9.8 años, respectivamente.

Información clave

Carrie Bourdow

Chief Executive Officer (CEO)

US$1.7m

Compensación total

Porcentaje del salario del CEO	40.9%
Permanencia del CEO	5.6yrs
Participación del CEO	0.5%
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	9.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Carrie Bourdow en comparación con los beneficios de Trevena?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$2m	US$682k	-US$40m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$1m	US$656k	-US$54m
Sep 30 2022	n/a	n/a	-US$61m
Jun 30 2022	n/a	n/a	-US$59m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$2m	US$637k	-US$52m
Sep 30 2021	n/a	n/a	-US$50m
Jun 30 2021	n/a	n/a	-US$41m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$3m	US$613k	-US$29m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$25m
Dec 31 2019	US$2m	US$563k	-US$25m
Sep 30 2019	n/a	n/a	-US$26m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$27m
Dec 31 2018	US$2m	US$418k	-US$31m
Sep 30 2018	n/a	n/a	-US$38m
Jun 30 2018	n/a	n/a	-US$49m
Mar 31 2018	n/a	n/a	-US$60m
Dec 31 2017	US$1m	US$341k	-US$72m

Compensación vs. Mercado: La compensación total de Carrie($USD1.00M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Carrie ha aumentado mientras la empresa no es rentable.

CEO

Carrie Bourdow (60 yo)

5.6yrs

Permanencia

US$1,664,855

Compensación

Ms. Carrie L. Bourdow has been Chief Executive Officer, President and Director at Trevena, Inc. since October 01, 2018 and serves as its Chairman since November 09, 2023. Ms. Bourdow served as an Executive...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Carrie Bourdow	President	5.6yrs	US$1.66m	0.51% $ 38.2k
Barry Shin	Executive VP	4.9yrs	US$1.01m	0.21% $ 15.9k
Mark Demitrack	Senior VP & Chief Medical Officer	6yrs	US$1.03m	0.20% $ 15.0k
Howard Rockman	Scientific Founder	no data	sin datos	sin datos
Joel Solomon	VP, General Counsel	no data	sin datos	sin datos
Michael Catalano	Vice President of Marketing	6.3yrs	sin datos	sin datos
Robert Yoder	Senior VP	5.4yrs	US$689.16k	0.12% $ 8.7k
Patricia Drake	Senior VP & Chief Commercial Officer	2.5yrs	sin datos	0.072% $ 5.4k

5.5yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TRVN es experimentado (5.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Carrie Bourdow	President	5.6yrs	US$1.66m	0.51% $ 38.2k
Howard Rockman	Scientific Founder	no data	sin datos	sin datos
William Schmidt	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jason Nunn	Independent Director	10.8yrs	US$76.11k	0.00093% $ 69.8
John LaMattina	Member of the Scientific Advisory Board	15.3yrs	sin datos	sin datos
Robert Lefkowitz	Member of Scientific Advisory Board	no data	sin datos	sin datos
Robert R. Ruffolo	Member of the Scientific Advisory Board	15.3yrs	sin datos	sin datos
Mark H. Corrigan	Independent Director	less than a year	US$55.87k	0% $ 0
Anne Phillips	Independent Director	10.3yrs	US$76.11k	0% $ 0
Scott Braunstein	Lead Independent Director	5.7yrs	US$70.11k	0% $ 0
Barbara Yanni	Independent Director	9.8yrs	US$76.58k	0% $ 0
Marvin Johnson	Independent Director	3.2yrs	US$61.11k	0% $ 0

9.8yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de TRVN se considera experimentada (9.8 años de antigüedad promedio).

Trevena Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Trevena, Inc., Annual General Meeting, Jun 13, 2024

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. Announces Board Changes

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Insufficient new directors

Recent updates

Trevena, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Market cap size

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 28%, revenue upgraded

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Revenue and earnings growth

Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement

Trevena Receives Non-Compliance Notice From Nasdaq Stock Market

Consensus revenue estimates increase by 725%

New major risk - Market cap size

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study

New major risk - Market cap size

Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023

Price target decreased by 39% to US$17.00

Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY

Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

Trevena Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$28.67

Insufficient new directors

Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator

Trevena, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Trevena Q2 2022 Earnings Preview

Trevena, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Trevena Gets an Additional 180 Days to Get Listing Compliance

Consensus revenue estimates fall by 36%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Trevena, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Trevena, Inc. Receives Notice to Cease Enrollment for TRV027 as Part of the ACTIV-4 Host Tissue Platform

Trevena, Inc. Announces Results from Pfound D Sedation, Respiratory Depression, Coma, and Death May Result from E Concomitant Use of Olinvyk

Consensus forecasts updated

Trevena, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$4.67

Insufficient new directors

Trevena, Inc. Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Trevena, Inc. Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder

Trevena, Inc. Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

Trevena Investor Presentation - Slideshow

Trevena, Inc. Announces TRV027 Selected by NIH-Funded ACTIV Initiative for COVID-19 Trial

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Trevena, Inc. Publishes New Analysis of Respiratory Safety Data from the OLINVYK Phase 3 Multi-Site